CS
BIIB icon

Credit Suisse’s Biogen BIIB Stock Holding History

Credit Suisse’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,900
Closed -$3.58M – 3662
2021
Q4 		$3.58M Buy
14,900
+9,700
+187% +$2.49M ﹤0.01% 2301
2021
Q3 		$1.47M Sell
5,200
-61,600
-92% -$20.2M ﹤0.01% 3050
2021
Q2 		$23.1M Sell
66,800
-59,500
-47% -$18M 0.01% 1075
2021
Q1 		$35.3M Sell
126,300
-36,600
-22% -$9.87M 0.02% 867
2020
Q4 		$39.9M Buy
162,900
+85,200
+110% +$22M 0.02% 812
2020
Q3 		$22M Sell
77,700
-11,800
-13% -$3.29M 0.01% 984
2020
Q2 		$23.9M Sell
89,500
-27,700
-24% -$8.33M 0.02% 857
2020
Q1 		$37.1M Sell
117,200
-83,800
-42% -$25.4M 0.03% 538
2019
Q4 		$59.6M Buy
201,000
+30,000
+18% +$8.32M 0.04% 457
2019
Q3 		$39.8M Buy
171,000
+55,400
+48% +$12.9M 0.03% 561
2019
Q2 		$27M Buy
115,600
+29,200
+34% +$6.74M 0.02% 747
2019
Q1 		$20.4M Buy
86,400
+10,700
+14% +$3.37M 0.02% 859
2018
Q4 		$22.8M Sell
75,700
-64,300
-46% -$20.5M 0.02% 733
2018
Q3 		$49.5M Buy
140,000
+85,000
+155% +$29.3M 0.04% 429
2018
Q2 		$16M Buy
55,000
+26,000
+90% +$7.31M 0.02% 959
2018
Q1 		$7.94M Buy
+29,000
New +$9M 0.01% 1396
2017
Q2 		– Sell
-20,000
Closed -$5.47M – 3830
2017
Q1 		$5.47M Sell
20,000
-35,000
-64% -$9.9M ﹤0.01% 1597
2016
Q4 		$15.6M Hold
55,000
– – 0.02% 947
2016
Q3 		$17.2M Buy
+55,000
New +$16.3M 0.02% 900

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's BIIB Position: Q1 2024 in Review

Credit Suisse reduced its Biogen (BIIB) stake by 8.4% in Q1 2024, selling an estimated $6.25M and leaving 291,725 shares worth $62.9M. The position accounts for 0.06% of the portfolio, ranked #311.

Credit Suisse first reported a position in BIIB in Q2 2013 and has held it in 44 quarters since. The position peaked at $283M in Q2 2015. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

  • Credit Suisse held 291,725 shares of Biogen worth $62.9M as of Q1 2024.
  • Credit Suisse sold 26,696 Biogen shares in Q1 2024, an estimated $6.25M.
  • Biogen made up 0.06% of Credit Suisse's portfolio in Q1 2024, its #311 holding.
  • Credit Suisse first reported a position in Biogen in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Biogen position peaked at $283M in Q2 2015.
  • 954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.